We could not find any results for:
Make sure your spelling is correct or try broadening your search.
REDWOOD CITY, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Company, today announced five posters, including new analyses from studies of Veltassa® (patiromer) for...
Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment...
REDWOOD CITY, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the Phase 4 TOURMALINE study, which compared the...
GLATTBRUGG, Switzerland, Aug. 4, 2016 (GLOBE NEWSWIRE) -- Galenica Group today announced that its indirect wholly owned subsidiary, Vifor Pharma USA Inc., is commencing today its previously...
Relypsa Inc. Acquisition May Not Be in the Best Interests of RLYP Shareholders PR Newswire NEW YORK, July 25, 2016 NEW YORK, July 25, 2016 /PRNewswire/ -- WeissLaw LLP is investigating possible...
RELYPSA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Relypsa, Inc. (RLYP) Over the Proposed Sale of the Company to Galenica Group Faruqi & Faruqi, LLP, a...
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board...
Ryan & Maniskas, LLP Announces Investigation of Relypsa, Inc. PR Newswire WAYNE, Pa., July 22, 2016 WAYNE, Pa., July 22, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating...
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Relypsa, Inc. -RLYP PR Newswire BALA CYNWYD, Pa., July 21, 2016 BALA CYNWYD, Pa., July 21...
Rigrodsky & Long, P.A.: Do you own shares of Relypsa, Inc. (NASDAQ GS: RLYP)? Did you purchase any of your shares prior to July 21, 2016? Do you think the proposed buyout...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions